Armitage James O 4

What Happened
James O. Armitage, a director of Cardiff Oncology, was reported to have been granted/acquired 40,565 shares on June 11, 2026. The Form 4 shows the shares were acquired at $0.00 per share and the transaction is reported as an award/grant (transaction code A) recorded as a derivative. Because the reported acquisition price is $0, the form does not list a cash purchase amount for the award.

Key Details

• Transaction date: 2026-06-11 (reported on Form 4 filed 2026-06-15) — filing appears to be within required reporting timeframe.
• Transaction type/code: A = Award/Grant; reported as a derivative acquisition.
• Shares involved: 40,565 shares acquired at $0.00 per share (no cash paid reported).
• Shares owned after transaction: not specified in the provided data.
• Footnotes/plan details: none provided in the summary data supplied.

Context
An "A" award typically reflects compensation (e.g., restricted stock or RSU settlement) rather than an open-market purchase or sale. Awards should not be read as direct buy/sell market sentiment but do reflect company compensation to insiders. This filing shows a compensation-related issuance to a director rather than a purchase or sale in the open market.